Compound tirzepatide cold sensitivity: what the data says

What did @sarahchismosa actually say?

Sarah is on her second 5mg shot of compounded tirzepatide and reporting zero side effects this week. Her main observations: appetite suppression has shifted from "couldn't eat" on 2.5mg to "can eat, just can't eat very much" on 5mg. The detail that's getting attention is that she's been "literally freezing" despite a 71-degree house, and she's not sure whether it's a side effect. She also mentions she doesn't think she's anemic, which she floats as a possible explanation for the cold sensitivity.

To her credit, she's not making definitive medical claims. She's reporting lived experience, which is exactly what patient content does well. But the cold symptom in particular deserves a closer look, because the explanation is more interesting than "possible side effect."

Does the science back this up?

Yes, with important nuance. The shift from intense nausea and food aversion at 2.5mg to manageable appetite suppression at 5mg is consistent with how tirzepatide behaves in dose-escalation trials. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that side effects, particularly GI symptoms, tend to peak during early dose escalation and moderate as the body adapts.

The cold sensitivity is where it gets genuinely interesting. Feeling cold during active weight loss is a well-documented physiological response. When caloric intake drops significantly, the body reduces thermogenesis to conserve energy. A 2021 paper by Rosenbaum and Leibel in Obesity Reviews documented reduced sympathetic nervous system activity and lower core temperature in calorie-restricted individuals. This isn't unique to GLP-1 agonists. It happens with any meaningful caloric deficit. Tirzepatide's dual GIP and GLP-1 receptor agonism does affect energy expenditure pathways, but the cold feeling is more likely driven by eating less than by the drug acting directly on temperature regulation.

What did they get right, and what's missing?

She got the appetite suppression trajectory right. The pattern of "couldn't eat anything" early, followed by "can eat, just less" is a classic GLP-1 response that many patients report and that dose-titration protocols are specifically designed to manage. That part tracks.

Where she's incomplete, not wrong but incomplete, is on the cold sensitivity. Ruling out anemia is reasonable thinking, but there are other explanations she doesn't mention. Rapid early weight loss changes fat mass distribution, which affects insulation. Reduced caloric intake suppresses metabolic rate. A 2019 analysis by Celi et al. in Journal of Endocrinological Investigation noted that even modest caloric restriction measurably reduces skin temperature and perceived warmth. The drug itself isn't necessarily doing this. Her body is responding to eating less.

She also doesn't distinguish between compounded tirzepatide and the FDA-approved brand Zepbound. These are not the same product. Compounded versions are not FDA-reviewed for safety, purity, or efficacy, and patients using them should understand that clinical trial data like SURMOUNT-1 applies to the approved drug, not compounded preparations.

What should you actually know?

Feeling cold on tirzepatide or any GLP-1 medication is real, common, and usually not alarming. But it's worth understanding why it happens so you're not chasing the wrong cause.

• Significant caloric reduction lowers your metabolic rate, which reduces heat production. This is biology, not a drug side effect per se.
• If cold sensitivity is severe, persistent, or comes with fatigue, hair loss, or brain fog, that warrants a conversation with a provider about thyroid function and, yes, anemia, not just self-ruling it out.
• The appetite suppression pattern Sarah describes, intense early suppression softening at higher doses, is consistent with published data, but individual responses vary widely.
• Compounded tirzepatide is not FDA-approved. It is not the same as Zepbound. Anyone using compounded versions should be under medical supervision and aware that third-party purity and dosing consistency is not guaranteed the way it is with approved products.
• If you're using a heating pad to get through the day, that's worth logging and mentioning to your provider. It's probably benign, but it's a data point.

The bottom line

Sarah's experience is largely consistent with what the clinical literature describes for tirzepatide users in early dose escalation. The cold sensitivity she's puzzling over is real and has a plausible metabolic explanation, it's just not the one she reached for. Her instinct to rule out anemia isn't wrong, it's just incomplete. The more likely driver is that she's eating significantly less, and her body is conserving energy accordingly. That's not a reason to panic. It is a reason to eat enough protein, stay hydrated, and keep your care team in the loop.